anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to medicine for infants to invigorate functions of the spleen and expel stagnation and a preparing method thereof. The medicine is formed by refining by using twenty-seven kinds of Chinese herbal medicine of ginseng, milk vetch, etc. as raw materials. An oral medicinal liquid dosage form is formed by that the ginseng is firstly decocted by adding water, and decoction liquid is filtered and concentrated for preparation. Then, twenty-six kinds of medicine of milk vetch, etc. are together decocted by adding water, and after decoction liquid is concentrated and filtered, an auxiliary agent is added. Next, spare concentrated solution is added, and water is regulated for fixing the volume. The medicine for infants to invigorate functions of the spleen and expel stagnation of the present invention has the efficiency of replenishing qi to invigorate the spleen, nourishing stomach, promoting digestion and relieving stasis. The present invention is suitable for infants with diseases of anorexia or apastia caused by deficiency of spleen qi and stomach qi, sallow complexion, lassitude, weakness of limbs, spongy muscle, body marasmus or excess puffiness, easy perspiration, no digestion of diet, loose and rot stool or stool containing apepsia food, etc.
For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but do not prevent relapse later on. In addition, chemotherapy associated toxicity is often problematic in MZL patients, who are mostly of advanced age. Thus, chemotherapy - free approaches are highly attractive for this patient group. Rituximab single agent is a widely used chemotherapy - free approach in MZL, but was significantly inferior compared to Rituximab/chlorambucil in a large randomized prospective clinical trial in treatment naïve MZL with a CR rate of 56 % vs. 80%, respectively (P\<0.001). Thus, it is the major aim to develop chemotherapy - free approaches for MZL, which approach efficacy of Rituximab/chemotherapy combinations, but avoid chemotherapy associated toxicities. This in particular important in MZL as many physicians are reluctant to treat these often elderly patients with more intense treatments and prefer single agent therapies in these very often well and long responding lymphoma subtype. The PI3K inhibitor Copanlisib has shown high clinical activity in indolent B - cell lymphomas among them MZL. Based on these observations it is the aim of this study to test the toxicity and efficacy of Copanlisib in combination with the anti-CD20 antibody Rituximab in patients with newly diagnosed or relapsed MZL in need of treatment, who are not eligible or failed local therapy, following the assumption that this novel chemotherapy - free combination is significantly more effective than Rituximab single agent therapy and at least as efficient as Rituximab/chemotherapy, but avoids chemotherapy - related toxicity.

The objective of the trial is to test the efficacy and toxicity of the treatment of Copanlisib/Rituximab in patients with MZL in need of treatment, who have failed or are not eligible for local therapy or relapsed after local or systemic therapy. For efficacy the rate of complete remissions (according to the GELA criteria for gastric MALT or to the Cheson 2007 criteria for non-gastric extranodal, nodal and splenic MZL) after induction therapy will be primarily analysed. For toxicity treatment associated adverse events, quality of life and cumulative incidence of secondary malignancies will be documented.
Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
Mouth dissolving pharmaceutical or neutraceutical composition comprising 1 to 70 % by weight of at least one pharmaceutical or neutraceutical active and 30 to 99 % by weight of pharmaceutically acceptable excipients including at least one potassium salt of cross linked acrylic polymer as super disintegrant in 1 to 30 % by weight of the pharmaceutically acceptable excipients, at least one pre- gelatinized starch or modified polysaccharide as softening agent in 5 to 50 % by weight of 'the pharmaceutically acceptable excipients and at least one water soluble channelizing agent in 2 to 90 % by weight of the pharmaceutically acceptable excipients. Potassium salt of crosslinked acrylic polymer as superdisintegrant is preferably Indion (414). The partially pre-gelatinized starch and 'the modified polysaccharide as softening agent are preferably Starch (1500) and Avicel RC (591) respectively. The water soluble channelizing agent is preferably selected from polysorbates or sodium lauryl sulfate or water soluble sugars such as dextrose, mannitol including xylitol or sucrose. The composition can be in the form of pellets, granules or tablets. Also methods of making the composition as pellets, granules or tablets are also disclosed.
Pain catastrophizing is a prominent psychological factor that is strongly correlated with pain. Although the complex properties of pain catastrophizing vary across different pain phases, the contribution of chronic pain to its progression from a general trait to a higher state remains unclear. This study aimed to examine the neural mechanisms and degree to which pain catastrophizing is reinforced in the context of primary dysmenorrhea (PDM), one of the most prevalent gynaecological complaints experienced by women of reproductive age. Altogether, 29 women with moderate-to-severe PDM were included in this study. Arterial spin labelling was used to quantify the cerebral blood flow (CBF) in each participant in both the pain-free and painful phases. The pain catastrophizing scale (PCS) was completed in two phases, and the Short-Form McGill Pain Questionnaire was completed in the painful phase. Compared with pain catastrophizing in the pain-free phase (PCSpf), pain catastrophizing in the painful phase (PCSp) is higher and positively correlated with the composite factor of menstrual pain. CBF analysis indicated that the PCSp is positively associated with CBF in the frontal cortex, hippocampus and amygdala. The reinforcement of pain catastrophizing correlates with CBF in the prefrontal cortex. Specifically, the medial prefrontal cortex, which correlates with pain state, plays a crucial role in mediating the reinforcing effect of pain in the PCSp. These results promote the mechanical comprehension of pain catastrophizing management in individuals with chronic pain.
The present invention provides a traditional Chinese medicinal preparation for preventing and curing exogenous wind-heat and preventing heatstroke. The prescription of the traditional Chinese medicinal preparation comprises seven traditional Chinese medicines of mussaenda pubescens Ait. F., scaly holly root, honeysuckle flower, narrowleaf screwtree root, chrysanthemum, asiatic pennywort herb and wild chrysanthemum which are matched scientifically and reasonably according to the theory of traditional Chinese medicines. The production method of the traditional Chinese medicinal preparation is characterized in that the medicines are prepared into granules, syrup, oral medicinal liquids, tablets, capsules, etc. by modern medical preparation production technology, such as water extraction, alcohol deposition, etc. The traditional Chinese medicinal preparation has the efficacy of clearing heat and toxic materials, resolving superficies syndrome by pungent and cool nature, promoting the production of the body fluid, relieving sore-throat, clearing summerheat and removing dampness by diuresis. The traditional Chinese medicinal preparation is mainly used for treating common cold, cough, sphagitis and urinary tract infection caused by exogenous wind-heat and preventing heatstroke. The traditional Chinese medicinal preparation has the advantages of obvious curative effect, wide treatment range and treatment of both exterior and interior.
All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
Patients receive sodium chloride as a placebo subcutaneously. It will be administered in the form of a pre-filled syringe for self-injection once a week for 12 months.
The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
Those participants who are automatically assigned to the brochure arm will be required to complete a 25-point initial test. Participants assigned to this arm will receive a web-based brochure on HPV and smear information (via free messaging services). At the conclusion of the brochure review, the same test will be administered again, and the participant's initial and second scores will be recorded in the case report form.
The present invention relates to a method for promoting CD34  +  Methods of differentiating cells into macrophages and polarizing cells into M2. The method comprises mixing human brain organoid derived mesenchymal stem cells N-MSC and umbilical cord blood derived CD34  +  Co-culturing the cells in a culture medium for 14-28 d to obtain CD34  +  Macrophages with differentiated cells. Macrophages and n-MSCs were combined in a quantitative ratio of 5:1 after co-culturing in a medium for 3d, IL-4 was used to stimulate for 24h to give M2 type macrophages. The method is simple to operate and has high differentiation efficiency. Using cell growth factors containing race attributes or not containing anyWhat in vitro cytokine culture environment is easy to obtain GMP-grade macrophages suitable for clinical application. When the umbilical cord blood and the N-MSC are co-transplanted, the occurrence of inflammatory reaction of transplantation can be reduced through the polarization of macrophages, and a theoretical basis is provided for clinical immune related inflammatory reaction diseases.
Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission. In some cases, the inhibitor of histamine independent itch signal transmission comprises an NK-1 receptor antagonist or the inhibitor of histamine independent itch signal transmission comprises a GRP receptor antagonist. In some cases, the method comprises administering two inhibitors of histamine independent itch signal transmission. For example, the inhibitors of histamine independent itch signal transmission can comprise an NK-1 receptor antagonist and a GRP receptor antagonist. In another embodiment, the invention provides a method of treating itch comprising administering to a subject suffering from itch an NK-1 receptor antagonist, a GRP receptor antagonist, and an AMPA receptor antagonist.
A drug infusion device determines whether an infusion program is stored within a memory. If so, a user is prompted to confirm usage of the program and a drug identifier, and to review the configuration of the device. If the program is not in the memory, the drug infusion device is enabled to receive an auto program with which it can configure itself. When auto program receipt is enabled, the drug infusion device waits for the auto program or for a selection for manual entry of the infusion program. A menu screen is displayed to indicate that the drug infusion device is waiting for the auto program, but the menu screen is not displayed if the auto program is already received. Therefore, a waiting for auto program menu screen may be avoided in many cases, reducing device setup time. In some embodiments, removal of a drug vial resets the device to a point after a power-on self-test and thus provides an easy method for resetting the device to a point that avoids unnecessary steps and expands a window of opportunity for receiving an auto program compared to prior work flows.
PURPOSE:To improve the absorptivity of Ca by using an acid-soluble fraction produced by deashing a crushed product containing bone or marrow. CONSTITUTION:Crushed material containing bone or marrow and produced by freezing and crushing animal bone, fish bone, poultry bone, etc., is dissolved or suspended in an aqueous solution of an organic acid or inorganic acid having pH of 2-3. The solution or suspension is stirred for 30min to several hours to effect the deashing of the crushed material. The deashed product is subjected to enzymatic decomposition by adding a proteinase (e.g. pepsin) thereto to obtain an acid-soluble fraction or water-soluble fraction having a molecular weight of 60,000-3,000. The fraction is desalted to obtain a bone-fortifying food, feed and medicine composed of a mixture of peptide and protein. The mixture is administered at a daily rate of 1,500-3,000mg to adult in several divided doses.
Colouring human hair comprises: (a) treating the hair with a first compsn. (I) contg. at least one synthetic direct dye and at least one direct vegetable dye; (b) allowing the first compsn. to act on the hair for 5-15 mins.; (c) applying a second compsn. (II) contg. at least one vegetable dye with a colour that harmonises with that of the first compsn; (d) allowing the second compsn. to act on the hair for 20-60 min; and (e) washing and drying the hair.
After ethics committee approval and parental consent were obtained, 119 patients undergoing genitourinary surgery or inguinal hernia repair under general anesthesia, were included in study. Patients with head or neck anomalies, syndromic patients, patients undergoing emergency surgery and patients with a history of difficult airway were excluded from the study. Patients were grouped according to their ages; Group I (1-2 years,n=38), Group II (3-5 years,n=46) and Group III (6-8 years,n=35). USG measurements were performed following sevoflurane induction in groups I and II. In group III, USG measurements were performed following premedication with intravenous midazolam 0.05 mg/kg . Thyrohyoid distance, glottic and subglottic diameters were measured with ultrasonography. The size of the endotracheal tube according to Bae's formula ( internal diameter of Endotracheal tube = 0.705 x subglottic diameter - 0.091) was calculated and recorded. Before intubation, endotracheal tube (cuffed/uncuffed) was selected using age-related formulas. In group II, anaesthesia induction was achieved with propofol 2 mg/kg. In all groups, endotracheal intubation was achieved with fentanyl 2μg/kg and rocuronium 0.6 mg/kg. Endotracheal tube size was considered as optimal when a leak was detected at 20-30cmH₂O inflation pressures. If a resistance was felt in the subglottic region, the tube was exchanged with a smaller and was exchanged with a larger (0.5 mm) size if a leak occurred at inflation pressures lower than 20cmH₂O. Intubation duration , Cormack-Lehane scores and Intubation Difficulty Scale scores were recorded. For comparison of age related formula and Bae 's formula, only patients who were intubated with un-cuffed endotracheal tube were evaluated.
Use of EMSAM in patients less than 12 years of age is contraindicated because of the potential for a hypertensive crisis [see Contraindications (4)].

Limited pharmacokinetic data with doses lower than in the commercially available formulations suggest that children under age 12 may be exposed to increased levels of selegiline compared to adolescents and adults, administered with and without dietary modifications, therefore, there may be an increased risk of hypertensive crisis, even at the lowest dose of EMSAM.

Efficacy has not been established in pediatric patients ages 12 to 17 years with MDD and EMSAM is not recommended for use in this age range [see Clinical Pharmacology (12.3)]. 

A multi-center, randomized, double-blind, placebo-controlled, flexible-dose trial in 308 adolescents (ages 12 to 17 years) with MDD failed to demonstrate the efficacy of EMSAM. Diagnosis of major depressive disorder (single episode or recurrent, moderate to severe) was based on according DSM-IV criteria and Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS). Enrolled patients had a Children’s Depression Rating Scale-Revised of ≥ 45 at the screening visit. Trial participants were randomized 1:1 to either EMSAM or matching placebo without forced titration for a period of 12 weeks. Active treatment consisted of EMSAM transdermal system at a dose of 6 mg per 24 hours, 9 mg per 24 hours, or 12 mg per 24 hours. The primary efficacy endpoint was the difference in total score on the Children’s Depression Rating Scale-Revised (CDRS-R) from baseline to the end of study (EOS) (Week 12). There was no observed difference in effect on CDRS-R Total Score at Week 12 (EOS) between treatments. The mean reduction in CDRS-R Total Score was 21.4 in the EMSAM-treated subjects and 21.5 in those receiving placebo treatment. Safety endpoints included physical examination, 12-lead electrocardiogram, respiration rate, temperature, supine and standing blood pressure and heart rate, application site assessments, and adverse events. Overall, safety findings were similar to those observed in EMSAM trials conducted in adults. Treatment-emergent adverse events reported by at least 5% of EMSAM-treated patients at a rate at least twice the placebo rate were insomnia (6%, 3%) and upper respiratory tract infection (7%, 3%).
Phytonadione aqueous colloidal solution of vitamin K1 for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors—II, VII, and X. Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the post-translational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma carboxyglutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood.

Phytonadione is readily absorbed following intramuscular administration. After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.

In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K dependent clotting factors.

The action of the aqueous colloidal solution, when administered intravenously, is generally detectable within an hour or two and hemorrhage is usually controlled within 3 to 6 hours. A normal prothrombin level may often be obtained in 12 to 14 hours.

In the prophylaxis and treatment of hemorrhagic disease of the newborn, phytonadione has demonstrated a greater margin of safety than that of the water-soluble vitamin K analogues.
The active Sefton (AS_ERS) is a traditional exercise referral programme providing highly discounted access to council operated leisure centres and a number of partner gyms. Within this access patients will have access to gym and swimming facilities (£2 per visit) and exercises classes (£3 per visit). During the patients first meeting with their LDO a progressive personalised exercise programme will be developed. Following this the patient will attend their local gym or leisure centre for an induction with a staff member(£7 one off fee), enabling them to attend the centre at any time and complete the designed exercise programme. All exercise programmes will be different, but in general will include moderate intensity exercise on gym equipment (treadmill, ergometer etc.) and some basic resistance training. Patients may replace these gym sessions with exercises classes run by the facility. Patients will be encouraged to exercise 3-5 time per week.
OBJECTIVES: The present study investigated the roles birthplace and acculturation play in sleep estimates among Hispanic/Latino population at the US-Mexico border.
MEASURES: Data were collected in 2016, from N = 100 adults of Mexican descent from the city of Nogales, AZ, at the US-Mexico border. Sleep was assessed with the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index categorized as none, mild, moderate, and severe, and Multivariable Apnea Prediction Index (MAP) categorized as never, infrequently, and frequently. Acculturation was measured with the Acculturation Rating Scale for Mexican-Americans II (ARSMA-II).
RESULTS: The sample consisted of majority Mexican-born (66%, vs. born in the USA 38.2%). Being born in the USA was associated with 55 fewer minutes of nighttime sleep (p = .011), and 1.65 greater PSQI score (p = .031). Compared to no symptoms, being born in the USA was associated with greater likelihood of severe difficulty falling asleep (OR = 8.3, p = .030) and severe difficulty staying asleep (OR = 11.2, p = .050), as well as decreased likelihood of breathing pauses during sleep (OR = 0.18, P = .020). These relationships remained significant after Mexican acculturation was entered in these models. However, greater Anglo acculturation appears to mediate one fewer hour of sleep per night, poorer sleep quality, and reporting of severe difficulty falling asleep and staying asleep.
CONCLUSIONS: Among individuals of Mexican descent, being born in the USA (vs Mexico) is associated with about 1 hour less sleep per night, worse sleep quality, more insomnia symptoms, and less mild sleep apnea symptoms. These relationships are influenced by acculturation, primarily the degree of Anglo rather than the degree of Mexican acculturation.